Treatment for pure red cell aplasia after major ABO‐incompatible allogeneic stem cell transplantation: a multicentre study
Authors:
- 12 April 2021
- journal article
- research article
- Published by Wiley in British Journal of Haematology
- Vol. 193 (4) , 814-826
Abstract
Summary: Pure red cell aplasia (PRCA) following allogeneic haematopoietic stem cell transplantation (aHSCT) with major ABO incompatibility is responsible for transfusion dependent anaemia, impaired quality of life and iron overload. We conducted a retrospective study, over a 10‐year period, which included all consecutive patients who received a major ABO mismatched aHSCT, to assess the impact of specific treatment on PRCA. We did not observe any PRCA in the 57 aHSCT issued from cord blood. Among the remaining 631 patients, cumulative incidence of PRCA was 10·5% [range 8·2–13.0]. The median duration of resolved PRCA was 171 days [IQR 116; 261]. Pre‐transplant high isohaemagglutinins titre was associated with an increased risk of PRCA (P < 10−4). PRCA did not affect overall survival (P = 0·95). Twenty‐two patients (33·3%) received at least one specific treatment. The most commonly used treatments were rituximab (17 patients) and donor lymphocyte infusion (DLI; seven patients). Regarding PRCA resolution, we did not observe a significant difference between treated or untreated subjects (HR = 0·93, 95% confidence interval (CI) 0·48– 1·80; P = 0·82). Similar results were observed with erythropoietin treatment (22 patients, HR = 0·86 95% CI: [0·47–1·57] P = 0·62). Our data do not support the use of erythropoietin, rituximab or DLI for the treatment of PRCA.Keywords
This publication has 68 references indexed in Scilit:
- Incidence and natural history of pure red cell aplasia in major ABO‐mismatched haematopoietic cell transplantationBritish Journal of Haematology, 2013
- Rapid Recovery from Chronic PRCA by MSC Infusion in Patient after Major ABO-Mismatched alloSCTCase Reports in Medicine, 2012
- Prevention of pure red cell aplasia after major or bidirectional ABO blood group incompatible hematopoietic stem cell transplantation by pretransplant reduction of host anti-donor isoagglutininsHaematologica, 2009
- The effect of donor leukocyte infusion on refractory pure red blood cell aplasia after allogeneic stem cell transplantation in a patient with myelodysplastic syndrome developing from kostmann syndromeInternational Journal of Hematology, 2007
- Impact of ABO incompatibility on engraftment and transfusion requirement after unrelated cord blood transplantation: a single institute experience in JapanBone Marrow Transplantation, 2007
- Treatment of resistant pure red cell aplasia after major abo‐incompatible bone marrow transplantation with human adipose tissue‐derived mesenchymal stem cellsAmerican Journal of Hematology, 2007
- ABO Blood Group Barrier in Allogeneic Bone Marrow Transplantation RevisitedTransplantation and Cellular Therapy, 2005
- Treatment of pure red cell aplasia after major ABO-incompatible peripheral blood stem cell transplantation by induction of chronic graft-versus-host diseaseBone Marrow Transplantation, 2002
- Anti-A isoagglutinin as a risk factor for the development of pure red cell aplasia after major ABO-incompatible allogeneic bone marrow transplantationBone Marrow Transplantation, 2000
- A and B blood group antigen expression on mixed colony cells and erythroid precursors: relevance for human allogeneic bone marrow transplantationBritish Journal of Haematology, 1984